Clinical trial
Phase1b/2 Trial Of AZA + APG1252 In Patients With High-Risk AML
NCT07508982 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase1b/2 Trial Of AZA + APG1252 In Patients With High-Risk AML
- Lead sponsor
- M.D. Anderson Cancer Center
- Phase
- Phase 1/2
- Overall status
- Recruiting
- Start date
- May 22, 2026
- Completion date
- December 12, 2031
- Enrollment
- 52 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
aml